122 related articles for article (PubMed ID: 21718818)
21. A case of G-CSF-producing invasive apical cancer resected following preoperative adjuvant therapy.
Takagi Y; Nakamura H; Miwa K; Adachi Y; Fujioka S; Haruki T; Taniguchi Y
Thorac Cardiovasc Surg; 2010 Aug; 58(5):304-6. PubMed ID: 20680910
[TBL] [Abstract][Full Text] [Related]
22. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
Zhang L; Yuan X; Chen Y; Du XJ; Yu S; Yang M
Gene; 2013 Mar; 517(1):60-4. PubMed ID: 23313300
[TBL] [Abstract][Full Text] [Related]
23. Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.
Hata A; Katakami N; Yoshioka H; Fujita S; Kunimasa K; Nanjo S; Otsuka K; Kaji R; Tomii K; Iwasaku M; Nishiyama A; Hayashi H; Morita S; Ishida T
Lung Cancer; 2011 Nov; 74(2):268-73. PubMed ID: 21529987
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
Mu XL; Li LY; Zhang XT; Wang SL; Wang MZ
BMC Cancer; 2004 Aug; 4():51. PubMed ID: 15318946
[TBL] [Abstract][Full Text] [Related]
25. Skin rash as a surrogate marker of clinical response of targeted therapy using gefitinib in advanced or metastatic non-small-cell lung cancer--a retrospective study.
Acharyya S; Sau S; Dasgupta P; Chakraborty A; Gangopadhyay S
J Indian Med Assoc; 2012 Jul; 110(7):474-6, 493. PubMed ID: 23520673
[TBL] [Abstract][Full Text] [Related]
26. Is palpation of the nonresected pulmonary lobe(s) required for patients with non-small cell lung cancer? A prospective study.
Cerfolio RJ; Bryant AS
J Thorac Cardiovasc Surg; 2008 Feb; 135(2):261-8. PubMed ID: 18242247
[TBL] [Abstract][Full Text] [Related]
27. Differential efficacy of gefitinib across age groups in treatment of advanced lung adenocarcinoma.
Wang H; Zhang G; Li P; Yan X; Wang Q; Zhu H; Qi G; Fan Q; Ma Z
Pharmazie; 2012 Jan; 67(1):80-5. PubMed ID: 22393836
[TBL] [Abstract][Full Text] [Related]
28. Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib.
Dhruva N; Socinski MA
J Clin Oncol; 2009 Aug; 27(22):e31-2. PubMed ID: 19487379
[No Abstract] [Full Text] [Related]
29. Surgical treatment of primary lung cancer with synchronous brain metastases.
Billing PS; Miller DL; Allen MS; Deschamps C; Trastek VF; Pairolero PC
J Thorac Cardiovasc Surg; 2001 Sep; 122(3):548-53. PubMed ID: 11547308
[TBL] [Abstract][Full Text] [Related]
30. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
31. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
Sun JM; Lee KH; Kim SW; Lee DH; Min YJ; Yun HJ; Kim HK; Song HS; Kim YH; Kim BS; Hwang IG; Lee K; Jo SJ; Lee JW; Ahn JS; Park K; Ahn MJ;
Cancer; 2012 Dec; 118(24):6234-42. PubMed ID: 22674612
[TBL] [Abstract][Full Text] [Related]
32. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
33. Pneumonectomy: calculable or non-tolerable risk factor in trimodal therapy for Stage III non-small-cell lung cancer?
Steger V; Spengler W; Hetzel J; Veit S; Walker T; Mustafi M; Friedel G; Walles T
Eur J Cardiothorac Surg; 2012 Apr; 41(4):880-5; discussion 885. PubMed ID: 22233799
[TBL] [Abstract][Full Text] [Related]
34. Restoration of gefitinib efficacy following chemotherapy in a patient with metastatic non-small cell lung cancer.
Li XD; Geng YT; Wu CP; Shen H; Sun J; Shu YQ; Yin YM
Onkologie; 2010; 33(8-9):466-9. PubMed ID: 20838064
[TBL] [Abstract][Full Text] [Related]
35. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
Argiris A; Mittal N
Lung Cancer; 2004 Mar; 43(3):317-22. PubMed ID: 15165090
[TBL] [Abstract][Full Text] [Related]
36. Extended pneumonectomy with partial resection of the left atrium, without cardiopulmonary bypass, for lung cancer.
Spaggiari L; D' Aiuto M; Veronesi G; Pelosi G; de Pas T; Catalano G; de Braud F
Ann Thorac Surg; 2005 Jan; 79(1):234-40. PubMed ID: 15620949
[TBL] [Abstract][Full Text] [Related]
37. The role and clinical value of EUS in a multimodality esophageal carcinoma staging program with CT and positron emission tomography.
Pfau PR; Perlman SB; Stanko P; Frick TJ; Gopal DV; Said A; Zhang Z; Weigel T
Gastrointest Endosc; 2007 Mar; 65(3):377-84. PubMed ID: 17321235
[TBL] [Abstract][Full Text] [Related]
38. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers.
Lee DH; Han JY; Lee HG; Lee JJ; Lee EK; Kim HY; Kim HK; Hong EK; Lee JS
Clin Cancer Res; 2005 Apr; 11(8):3032-7. PubMed ID: 15837758
[TBL] [Abstract][Full Text] [Related]
39. Clinical and molecular predictors of recurrence in stage I non-small cell lung cancer.
Starnes SL; Pathrose P; Wang J; Succop P; Morris JC; Bridges J; Kupert EY; Anderson M
Ann Thorac Surg; 2012 May; 93(5):1606-12. PubMed ID: 22440368
[TBL] [Abstract][Full Text] [Related]
40. Diffuse micronodular pulmonary metastasis of lung adenocarcinoma predicts gefitinib response in association with epidermal growth factor receptor mutations.
Kobayashi M; Takeuchi T; Bandobashi K; Uemura Y; Ogawa Y; Ohtsuki Y; Taguchi H
Anticancer Res; 2006; 26(2B):1621-6. PubMed ID: 16619582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
